Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Share-based Compensation (2021 - 2025)

Historic Share-based Compensation for InMed Pharmaceuticals (INM) over the last 5 years, with Q3 2025 value amounting to $20205.0.

  • InMed Pharmaceuticals' Share-based Compensation fell 3024.1% to $20205.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $110547.0, marking a year-over-year decrease of 2186.77%. This contributed to the annual value of $119307.0 for FY2025, which is 1336.61% down from last year.
  • InMed Pharmaceuticals' Share-based Compensation amounted to $20205.0 in Q3 2025, which was down 3024.1% from $26729.0 recorded in Q2 2025.
  • In the past 5 years, InMed Pharmaceuticals' Share-based Compensation registered a high of $214779.0 during Q4 2021, and its lowest value of $18264.0 during Q4 2023.
  • In the last 5 years, InMed Pharmaceuticals' Share-based Compensation had a median value of $40480.0 in 2023 and averaged $73722.1.
  • In the last 5 years, InMed Pharmaceuticals' Share-based Compensation crashed by 7841.04% in 2023 and then soared by 2680.14% in 2024.
  • Quarter analysis of 5 years shows InMed Pharmaceuticals' Share-based Compensation stood at $214779.0 in 2021, then plummeted by 67.11% to $70638.0 in 2022, then plummeted by 74.14% to $18264.0 in 2023, then rose by 26.8% to $23159.0 in 2024, then dropped by 12.76% to $20205.0 in 2025.
  • Its Share-based Compensation stands at $20205.0 for Q3 2025, versus $26729.0 for Q2 2025 and $40454.0 for Q1 2025.